OPCH Earnings

OPCH reported its earnings on 2026-04-30, showcasing a revenue of 1.35B against an estimate of 1.40B, resulting in a -3.52% surprise. The EPS was 0.4, surpassing the expected 0.37 by 8.11%. The stock experienced a -24.34% price change on the earnings day and a -20.73% change over the next five days, reflecting market reactions to the results.

Following OPCH's earnings announcement on 2026-04-30, the stock price moved by -24.34% on the day of the release. Over the subsequent five days, it saw a -20.73% change. Historically, OPCH's stock price tends to shift by an average of 7.54% in the 10 days leading up to earnings and -0.86% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate OPCH's annual revenue to reach 1.52B, while the EPS is projected at 0.37. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between OPCH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OPCH's stock price typically moves by 7.54% in the 10 days before its earnings and -0.86% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.37 and revenue of 1.52B.

The earnings call reveals mixed signals: while there are positive aspects such as strong performance in acute therapies and growth in the IG Neuro portfolio, there are significant headwinds from the Stelara transition and increased gross profit headwinds. The company's confidence in its guidance and strategic initiatives are offset by concerns about competitive pressures and unclear management responses in some areas. The market cap suggests moderate sensitivity, leading to a neutral prediction for stock price movement over the next two weeks.